Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

Summary

This study evaluates the use of Colchicine in adults over 40 years of age who have suffered an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other defined causes. Patients will be randomised to 0.5 mg/day of Colchicine plus usual care, or to usual care alone. To investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (defined as antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice) compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis

Timeline

Start

2016-12-12

Primary completion

2024-01-31

Completion

2024-01-31

Publications

• Results Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, Collins R, Cronin S, Czlonkowska A, Desfontaines P, De Pauw A, Evans NR, Fischer U, Fonseca C, Forbes J, Hill MD, Jatuzis D, Korv J, Kraft P, Kruuse C, Lynch C, McCabe D, Mikulik R, Murphy S, Nederkoorn P, O'Donnell M, Sandercock P, Schroeder B, Shim G, Tobin K, Williams DJ, Price C. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet. 2024 Jul 13;404(10448):125-133. doi: 10.1016/S0140-6736(24)00968-1. Epub 2024 Jun 7.
• Synnott P, Walsh C, Weimar C, Purroy F, Price C, Fonseca AC, Hill M, Jatuzis D, Korv J, Kruuse C, Mikulik R, Nederkoorn P, Czlonkowska A, Fischer U, Nabavi DG, Harbison J, Cassidy T, O'Connor M, Iversen HK, Adie K, Lemmens R, Kelly PJ; CONVINCE investigators. Contemporary achievement of guideline recommendations for blood pressure management after stroke in the CONVINCE trial. Eur Stroke J. 2026 Jul 6;11(7):aakag051. doi: 10.1093/esj/aakag051.
• Maes L, Verschuere C, Walsh C, Weimar C, Purroy F, Price C, Fonseca C, Hill MD, Jatuzis D, Korv J, Kruuse C, Mikulik R, Nederkoorn P, Czlonkowska A, Fischer U, McCormick M, Castellanos M, Baptista M, Marto JP, Thavanesan K, Williams DJ, Kelly P, Lemmens R; CONVINCE investigators. Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial. Eur Stroke J. 2026 Apr 6;11(4):aakag033. doi: 10.1093/esj/aakag033.
• Maes L, Walsh C, Weimar C, Purroy F, Price C, Clarke B, Castro P, Czlonkowska A, Cuadrado-Godia E, Fischer U, Fonseca AC, Hill MD, Jatuzis D, Korv J, Kruuse C, Mikulik R, Nederkoorn PJ, Sztriha L, Thieme M, Kelly P, Lemmens R. Effect of colchicine for secondary prevention according to stroke subtype: A secondary analysis of the CONVINCE randomized trial. Int J Stroke. 2025 Dec 2:17474930251406818. doi: 10.1177/17474930251406818. Online ahead of print.
• Akl E, Sahami N, Labos C, Genest J, Zgheib A, Piazza N, Jolly S. Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease. J Interv Cardiol. 2024 Mar 12;2024:8646351. doi: 10.1155/2024/8646351. eCollection 2024.
• Bouabdallaoui N, Tardif JC. Colchicine in the Management of Acute and Chronic Coronary Artery Disease. Curr Cardiol Rep. 2021 Jul 16;23(9):120. doi: 10.1007/s11886-021-01560-w.

Drugs

Indications